Second-line therapy for ovarian cancer
Markman, M.
Clinical Advances in Hematology and Oncology H&o 6(6): 421-422
2008
ISSN/ISBN: 1543-0790 PMID: 18567987 Document Number: 615998
Document emailed within 1 workday
Related Documents
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15Geary, M.; Foley, M.; Lenehan, P.; Murphy, J.; Fennelly, J. 1995: Recurrent ovarian carcinoma: diagnosis and second-line therapy Irish Medical Journal 88(2): 68-70
Kijima, T.; Kubota, N.; Nishio, K. 1994: Establishment of a CPT-11-resistant human ovarian cancer cell line Anticancer Research 14(3a): 799-803
Harpole, J.L.; Tucci, M.; Benghuzzi, H. 2015: Pathophysiological Effects of Thymoquinone and Epigallocatechin-3-Gallate on SK-OV-3 Ovarian Cancer like Cell Line Biomedical Sciences Instrumentation 51: 31-39
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Argenta, P.A.; Ormsby, R.R.; Downs, L.S.; Judson, P.L.; Ghebre, R.; Carson, L.F. 2008: Routine pelvic examination during front-line chemotherapy for ovarian cancer: should it play a role? Journal of Reproductive Medicine 53(1): 3-7
Ota, T.; Takeshima, N.; Takizawa, K. 2011: Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly? European Journal of Gynaecological Oncology 32(5): 471-475
Topuz, E.; Saip, P.; Aydmer, A.; Salihoğlu, Y.; Berkman, S.; Bengisu, E. 1998: Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer European Journal of Gynaecological Oncology 19(3): 265-270
Xin, T.; Zhang, F.B.; Sui, G.J.; Jin, X.M. 2012: Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity British Journal of Biomedical Science 69(2): 62-66
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Riedinger, J.M.; Eche, N.; Basuyau, J.P.; Daver, A.; Touzery, C.; Mayer, F.; Coudert, B.; Fargeot, P.; Chauffert, B.; de Gislain, C.; Zanetta, S. 2002: Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles Annales de Biologie Clinique 60(2): 183-191
Zhou, Y.; Chen, H.; Yang, Q. 1996: Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance Zhonghua Yi Xue Za Zhi 76(9): 680-683
Kietpeerakool, C.; Tiyayon, J.; Suprasert, P.; Kanjanavanit, R.; Srisomboon, J. 2006: Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer Journal of the Medical Association of Thailand 89(11): 1805-1810
Markowska, J.; Madry, R.ła.; Kierzkowski, J.; Malicki, J.; Roszak, A.; Lubin, J.; Bratos, K. 2003: Radioimmunotherapy in patients with ovarian cancer in complete remission after the first line surgery and chemotherapy after second look laparoscopy procedure Ginekologia Polska 74(9): 799-804
Wu, H.-j.; Hao, Q.; Wang, K.; Liu, W.-x.; Ma, D. 2011: Effects of PTEN gene on invasion and migration of ovarian cancer cell line A2780 and related mechanisms Zhonghua Zhong Liu Za Zhi 33(3): 165-168
Chen, X.; Mou, H.; Dai, H. 1997: Induction of apoptosis in human ovarian cancer cell line HO-8910 by transforming growth factor beta 1 Zhonghua Fu Chan Ke Za Zhi 32(7): 436-439
Lin, F.-f.; Chen, H.-z.; Xie, X.; Ye, D.-f. 2003: Down-regulation of vascular endothelial growth factor expression in ovarian cancer cell line SKOV3 by interferon-gamma Zhonghua Fu Chan Ke Za Zhi 38(3): 150-153; 3-1
Zhang, Z.-M.; Zhang, F.-H.; Wang, X.-M.; Zhang, C.; Liu, J.; Gu, L.-M.; Li, Q.-H.; Shan, B.-E.; Tagawa, M. 2008: Enhanced expression of CD40L cDNA on ovarian cancer cell line OVHM induces the secretion of Th1 cytokines from dendritic cells Zhonghua Zhong Liu Za Zhi 30(3): 174-178
Mayerhofer, K.; Bodner-Adler, B.; Bodner, K.; Leodolter, S.; Kainz, C. 2000: Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity Anticancer Research 20(5c): 4047-4050
Chen, X.; Zheng, S.; Gao, Y.; Dai, H.; Mou, H.; Yang, H. 1998: Growth regulation of ovarian cancer cell line HO-8910 by transforming growth factor beta 1 in vitro Chinese Medical Journal 111(6): 546-550